Amgen: Blockbusters, Emerging Therapies, And Investment Potential

Jan 6, 2025 · Amgen: Blockbusters, Emerging Therapies, And Investment Potential. Jan. 05, 2025 7:18 PM ET Amgen Inc. (AMGN) Stock 3 Comments. ... EVENITY, another of Amgen’s …

CouponFollow Extension

$3
OFF

Amgen Adds Potential Blockbuster Drug With $3.7 Billion …

2 weeks from now

Aug 4, 2022 · U.S. drugmaker Amgen Inc is buying ChemoCentryx Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders.

ibtimes.com

$49.06
OFF

Amgen Is Investing $49.06B On Biopharma. What Opportunities …

2 weeks from now

Challenges in this category include developing therapies that can manage chronic conditions without severe side effects. Amgen's second-largest investment is in rare diseases, allocating …

scitodate.com

5%
OFF

Are Wall Street Analysts Predicting Amgen Stock Will Climb Or Sink?

2 weeks from now

3 days ago · Amgen's shares recovered 1.5% following its Q3 earnings release on Oct. 30 due to the company’s stronger-than-expected adjusted EPS of $5.58. The revenue growth of 23% …

nasdaq.com

19%
OFF

Amgen Q4: Good Quarter, Ok Guidance, But MariTide Concerns …

2 weeks from now

1 day ago · Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

seekingalpha.com

$50
OFF

Merck Touts 20 New ‘blockbuster’ Drugs In Development ... - Fortune

2 weeks from now

3 days ago · Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential. BY Hallie Steiner. Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news …

fortune.com

FAQs about Amgen: Blockbusters, Emerging Therapies, And Investment Potential Coupon?

Is Amgen a good investment?

The company's future growth potential, particularly in the obesity market, has garnered significant attention from analysts and investors. While challenges remain, including intense competition and regulatory hurdles, Amgen's strong R&D focus and diverse portfolio position it well for potential long-term success. ...

Does Amgen have a drug portfolio?

Amgen’s portfolio spans several therapeutic areas, including: Oncology/Hematology: Drugs like Kyprolis (for multiple myeloma) and Blincyto (for acute lymphoblastic leukemia) highlight Amgen’s strong presence in cancer treatment. Cardiovascular Disease: Repatha, a PCSK9 inhibitor, is a notable product aimed at reducing cardiovascular risk. ...

Is Amgen a pharma company?

Amgen was founded in 1980 as one of the first venture-backed biotechnology companies. Its first two therapies were Epogen and Neupogen. Today, the pharma giant operates globally and is a major player in therapeutic biologicals for general medicine, rare diseases, inflammation, and oncology with multiple blockbuster drugs. ...

Is Amgen a good biotechnology company?

wildpixel/iStock via Getty Images Thesis Amgen Inc. (NASDAQ:AMGN) is a biotechnology powerhouse with an excellent track-record on developing and commercialising products targeting four main therapeutic areas: general medicine, rare disease, oncology and inflammation/immunology. ...

How does Amgen collaborate with other biotech companies?

Collaborations and Licensing: Amgen frequently collaborates with other biotech and pharmaceutical companies, leveraging its advanced research capabilities. These partnerships often involve licensing agreements, milestone payments, and royalties. ...

Should you buy Amgen (AMGN) in 2025?

Despite strong performance, Amgen's high debt levels and cautious 2025 guidance lead to a Hold rating, with Novo and Regeneron preferred. JHVEPhoto Investment Overview Amgen (NASDAQ:AMGN), the Thousand Oaks, California based Pharma giant, announced its Q4 and full-year 2024 earnings yesterday, February 4th 2025. Let's look at the key numbers. ...